We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $111M
1-Year Est. Return 74.4%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.4%
3 Year Est. Return
-95.55%
5 Year Est. Return
-99.44%
10 Year Est. Return
-99.5%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
+$145M
Cap. Flow %
8.42%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Miscellaneous 81.15%
2 Healthcare 18.37%
3 Financials 0.23%
4 Technology 0.2%
5 Consumer Staples 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADYX
176
DELISTED
Adynxx Inc
ADYX
$649K 0.04%
18,340
-3,689
-17% -$154K
FOMX
177
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$648K 0.04%
58,338
-143,226
-71% -$1.35M
CSBR icon
178
Champions Oncology
CSBR
$66.4M
$641K 0.04%
253,504
-285,089
-53% -$555K
VTVT icon
179
vTv Therapeutics
VTVT
$120M
$640K 0.04%
3,314
-55
-2% -$12.6K
BCLI
180
DELISTED
BRAINSTORM CELL THERAPUTC
BCLI
$637K 0.04%
16,718
-12,915
-44% -$448K
INSM icon
181
Insmed
INSM
$26.2B
$636K 0.04%
+48,043
New +$655K
SIEN
182
DELISTED
Sientra, Inc.
SIEN
$605K 0.04%
+7,097
New +$590K
OPGN
183
DELISTED
OpGen, Inc
OPGN
$604K 0.04%
5
-17
-77% -$2.11M
LJPC
184
PUT
DELISTED
La Jolla Pharmaceutical Company
LJPC
$589K 0.03%
+336
New +$6.44K
LUMO
185
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$579K 0.03%
6,254
+2,414
+63% +$272K
FOLD
186
PUT
DELISTED
Amicus Therapeutics
FOLD
$567K 0.03%
1,140
-1,142
-50% -$7.9K
GRDX
187
GridAI Technologies Corp
GRDX
$21.5M
$564K 0.03%
+1
New +$578K
MTFBW
188
DELISTED
Motif Bio plc Warrants to Purchase ADRs
MTFBW
$550K 0.03%
+426,170
New +$541K
SCON
189
DELISTED
Superconductor Technologies Inc.
SCON
$535K 0.03%
4,347
+1,842
+74% +$346K
BPMC
190
PUT
DELISTED
Blueprint Medicines
BPMC
$533K 0.03%
190
– –
HALO icon
191
PUT
Halozyme
HALO
$12.1B
$526K 0.03%
+532
New +$5.83K
SAGE
192
PUT
DELISTED
Sage Therapeutics
SAGE
$521K 0.03%
102
-163
-62% -$7.68K
ALNY icon
193
Alnylam Pharmaceuticals
ALNY
$31.9B
$518K 0.03%
+13,823
New +$579K
PCRX icon
194
PUT
Pacira BioSciences
PCRX
$960M
$514K 0.03%
159
– –
NDRM
195
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$511K 0.03%
+23,033
New +$431K
MNKD icon
196
PUT
MannKind Corp
MNKD
$1.14B
$499K 0.03%
1,568
-10,893
-87% -$31.5K
ABUS icon
197
CALL
Arbutus Biopharma
ABUS
$1B
$498K 0.03%
2,033
+84
+4% +$244
MRTX
198
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$474K 0.03%
99,735
– –
FLXN
199
PUT
DELISTED
Flexion Therapeutics, Inc.
FLXN
$472K 0.03%
248
+46
+23% +$879
SSKN
200
DELISTED
Strata Skin Sciences
SSKN
$455K 0.03%
20,696
+680
+3% +$17.4K
6 7
8
9 10

Similar funds

IWA
Independent Wealth Advisors Cary, North Carolina $111M AUM
BFA
Ballast Financial Advisors West Chester, Pennsylvania $110M AUM
WPWM
Western Pacific Wealth Management Lake Forest, Illinois $111M AUM 26.64% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $111M AUM 205.39% 1-Year Est. Return
ZS
Zenith Solutions Philadelphia, Pennsylvania $110M AUM
KC
Karras Company Roy, Utah $110M AUM
FI
FinArc Investments Norwood, Massachusetts $110M AUM
CIM
Catalyst Investment Management Windham, New Hampshire $110M AUM

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management deployed $145M of net new capital in Q4 2016, opening 67 new positions and adding to 88 existing holdings. Its largest new stake was Eli Lilly: 213,113 shares worth $15.7M.

By sector, the portfolio is most concentrated in Miscellaneous at 81% of assets, down from 90% a quarter earlier, followed by Healthcare and Financials.

On the sell side, the largest reduction was Regenxbio, an estimated $4.1M trimmed.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.